Bayer Wins EU Panel's Recommendation for Eye Disease Drug's New Indication

10:37 AM EST, 12/12/2025 (MT Newswires) -- Bayer (BAYN.F) said a European Medicines Agency committee issued a positive opinion for its 8-milligram Eylea for the treatment of patients with visual impairment due to macular edema following retinal vein occlusion. The Committee for Medicinal Products for Human Use's recommendation is based on the results of the late-stage Quasar study, where patients treated with 8-mg Eylea, or aflibercept, every two months following three or five preliminary monthly injections, recorded non-inferior visual acuity gains and robust fluid control at 36 weeks, compared with patients taking 2-mg Eylea monthly, according to a Friday release. The German biopharmaceutical company said the European Commission's final decision is expected in the coming weeks. It noted that the 8-mg Eylea is already approved for the treatment of neovascular age-related macular degeneration and diabetic macular edema within the European Union.